Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

BMY, Pfizer Records Consistent Results In Sub-analysis Of Eliquis Vs. Warfarin

Bristol-Myers Squibb Co. (BMY: Quote) and Pfizer Inc. (PFE: Quote) said the Phase III Aristotle trial of Eliquis in comparison with warfarin for the the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation were consistent with the overall results of the Aristotle trial. Further, the companies said the Eliquis compared with warfarin reduced stroke or systemic embolism, caused fewer major bleeding events, and reduced all-cause mortality in NVAF patients with or without valvular heart disease or VHD.

The Aristotle trial excluded patients with clinically significant mitral stenosis, or a mechanical prosthetic heart valve.

The results of the sub analysis were presented in an oral session today at the ESC Congress 2013 in Amsterdam, The Netherlands.

The subanalysis evaluated Eliquis compared to warfarin in patients with or without other types of VHD, who were eligible for enrollment in the Aristotle

trial, including mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or valve surgery. 4,808 patients participated in the sub analysis.

Eliquis is an oral inhibitor of blood clotting protein Factor Xa.

Click here to receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A ban on athletes using stamina-boosting gases - xenon and argon - came into effect on Monday. The World Anti-Doping Agency (WADA) said Hypoxia-Inducible Factor (HIF) activators Xenon and Argon have been added to the 2014 List of Prohibited Substances and Methods List following the required three-month notice period and UNESCO's communication to all States Parties. A recommendation to revise the British manufacturing growth eased further in August to its lowest level in 14 months as output and demand increased at slower rates, survey results from Markit Economics showed Monday. The Markit/CIPS Purchasing Managers' Index dropped to 52.5 from a revised 54.8 in July. Economists had expected the score to fall to 55.1 from July's original figure of 55.4. Consumers spent less in July than in the previous month, a surprise retreat that complicates the prevailing belief that the U.S. economic situation is improving. Along with the unexpected drop in spending, government figures released on Friday showed that incomes rose at a slower pace in July than in the previous month. Meanwhile, data on prices indicated that inflation pressures remain tame.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.